Cantor Fitzgerald’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-688
Closed -$16.7K 498
2025
Q2
$16.7K Buy
+688
New +$16K ﹤0.01% 411
2023
Q4
Sell
-473,793
Closed -$15.7M 475
2023
Q3
$15.7M Sell
473,793
-48,250
-9% -$1.71M 0.42% 83
2023
Q2
$19.1M Sell
522,043
-7,022
-1% -$273K 0.44% 85
2023
Q1
$21.6M Buy
529,065
+130,100
+33% +$5.62M 0.46% 60
2022
Q4
$20.4M Buy
398,965
+5,169
+1% +$248K 0.44% 62
2022
Q3
$17.2M Sell
393,796
-828,092
-68% -$40.2M 0.38% 67
2022
Q2
$64.1M Buy
+1,221,888
New +$62.3M 1.24% 5

Other funds holding PFE

Cantor Fitzgerald's PFE Position: Q3 2025 in Review

Cantor Fitzgerald sold out of Pfizer (PFE) in Q3 2025, closing a stake of 688 shares — an estimated $16.7K sold.

Cantor Fitzgerald first reported a position in PFE in Q2 2022 and held it in 7 quarters. The position peaked at $64.1M in Q2 2022. 2,811 funds tracked by Wall St. Rank hold PFE as of Q3 2025.

  • Cantor Fitzgerald reported no remaining Pfizer position as of Q3 2025 after selling out during the quarter.
  • Cantor Fitzgerald sold 688 Pfizer shares in Q3 2025, an estimated $16.7K.
  • Cantor Fitzgerald first reported a position in Pfizer in Q2 2022 and held it in 7 quarters.
  • Cantor Fitzgerald's Pfizer position peaked at $64.1M in Q2 2022.
  • 2,811 funds tracked by Wall St. Rank held Pfizer as of Q3 2025.

Based on Cantor Fitzgerald's 13F filing for Q3 2025, filed 14 Nov 2025.